Summary
Between 1984–1989, 44 patients with stage I–II low grade lymphoma were treated prospectively with sequential chemotherapy and involved-field radiotherapy. The chemotherapy was cyclophosphamide, vincristine, prednisone, and bleomycin (COP-Bleo); doxorubicin was included (CHOP-Bleo) for patients with adverse prognostic features (high LDH; extranodal sites; bulky nodes). Of the 44 patients, 37 had measurable disease and all have responded. With a median follow-up of 32 months, the 5-year survival and failure-free survival were 89% and 74%, respectively. Compared to past experience with involved-field radiotherapy alone, the failure-free survival is significantly better with COP-Bleo plus radiotherapy. The potentially cured fraction has risen from 40% to 74%.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984; 10: 489–97.
Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS. Analysis of non-Hodgkin’s lymphomas with nodular and favorable histologies, stage I and II. Cancer 1983; 52: 2300–7.
McLaughlin P, Fuller LM, Velasquez WS, Sullivan-Halley JA, Butler JJ, Cabanillas F Stage I—II follicular lymphoma. Treatment results for 76 patients. Cancer 1986; 58: 1596–602.
Gomez GA, Barcos M, Krishnamsetty RM, Panahon AM, Han T, Henderson ES. Treatment of early stages I and II nodular, poorly differentiated lymphocytic lymphoma. Am J Clin Oncol 1986; 9: 40–4.
Lawrence TS, Urba WJ, Steinberg SM et al. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiation Oncology Biol Phys 1988; 14: 417–24.
Richards MA, Gregory WM, Hall PA et al. Management of localized non-Hodgkin’s lymphoma: the experience at St. Bartholomew’s hospital 1972–1985. Hemal Oncol 1989; 7: 1–18.
Heifetz LJ, Fuller LM, Rodgers RW et al. Laparotomy findings in lymphangiogram-staged I and II non-Hodgkin’s lymphomas. Cancer 1980; 45: 2778–86.
Goffinet DR, Warnke R, Dunnick NR et al. Clinical and Surgical (Laparotomy) Evaluation of Patient with Non-Hodgkin’s Lymphomas. Cancer Treat Rep 1977; 61: 981–92.
Kaplan EL, Meier P. Non-Parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
Gehan EA. A generalized Wilcoxan test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203–23.
Zuckerman KS, LoBuglio AF, Reeves JA. Chemotherapy of intermediate and high grade non-Hodgkin’s lymphomas with a high-dose doxorubicin-containing regimen. J Clin Oncol 1990; 8: 248–56.
Cabanillas F, Freireich EJ. Intensive treatment of nodular non-Hodgkin’s lymphoma. In: Wiernik PH (ed.). Controversies in Oncology. John Wiley and Sons, New York, 1982; pp 31–43.
Rosenberg SA. Is intensive treatment of favorable non-Hodgkin’s lymphoma necessary? In: Wiernik PH (ed.). Controversies in Oncology. John Wiley and Sons, New York, 1982; pp 45–60.
Romaguera JE, McLaughlin P, North L et al. Multivariate analysis of prognostic factors in stage IV follicular low grade lymphoma: A risk model. J Clin Oncol (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
McLaughlin, P. et al. (1991). Stage I–II low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy. In: Ultmann, J.E., Samuels, B.L. (eds) Annals of Oncology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7305-4_21
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7305-4_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7294-1
Online ISBN: 978-1-4899-7305-4
eBook Packages: Springer Book Archive